Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Bacil Pharma responded to a BSE query regarding significant movement in the price and trading volume of its securities. The company stated that it is not in possession of any unpublished price sensitive information (UPSI) or any material development that could explain the price movement. It confirmed full compliance with SEBI's Listing Obligations and Disclosure Requirements (LODR) Regulations, 2015, and said all required disclosures have been made to the stock exchange within prescribed timelines. The company attributed the recent price fluctuations to purely market-driven factors and reaffirmed its commitment to corporate governance and timely disclosures. The response was signed by Director Chaitali Kalpataru Shah on 24th February 2026.
For retail investors, this is a standard clarification rather than a negative event — the company is denying any hidden news behind the price move. However, unexplained price swings combined with no disclosure often mean the stock is volatile and speculative, so investors should watch for any further announcements or unusual trading activity.